Jianqin Lu
- Associate Professor, Pharmaceutical Sciences
- Assistant Professor, BIO5 Institute
- Member of the Graduate Faculty
- Professorship, Ware Endowed
Contact
- (520) 626-1786
- Pharmacy, Rm. 422
- Tucson, AZ 85721
- lu6@arizona.edu
Biography
Dr. Lu obtained B.S. in Pharmacy from Hunan University of Chinese Medicine, Changsha, China in 2010, and was conferred a Ph.D. degree in Pharmaceutics (Drug Delivery/Nanomedicine) at the School of Pharmacy, University of Pittsburgh in 2014. During 2015, Dr. Lu was a NIH Postdoctoral Scholar at Department of Chemistry, The University of Chicago. From 2016 to 2019, Dr. Lu was a NIH Postdoctoral Scholar/NIH NRSA T32 Postdoctoral Fellow in Nanomedicine/Tumor Immunology at California NanoSystems Institute, University of California, Los Angeles, where Dr. Lu spearheaded the nano-enabled cancer immunotherapy via simultaneously instigating immunogenic cell death and reversing immune checkpoints.
Degrees
- Ph.D. Pharmaceutics
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Interests
No activities entered.
Courses
2024-25 Courses
-
Directed Research
PHSC 792A (Spring 2025) -
Independent Study
PCOL 399 (Spring 2025) -
Independent Study
PCOL 499 (Spring 2025) -
Pharmaceutics Research
PHSC 596C (Spring 2025) -
Research
PHSC 900 (Spring 2025) -
Drug Delivery Systems
PCOL 355 (Fall 2024) -
Independent Study
PCOL 399 (Fall 2024) -
Independent Study
PCOL 499 (Fall 2024) -
Introduction to Pharmacology
PCOL 501 (Fall 2024) -
Introduction to Pharmacology
PHSC 501 (Fall 2024) -
Research
PHSC 900 (Fall 2024)
2023-24 Courses
-
Directed Research
BME 492 (Spring 2024) -
Independent Study
PCOL 399 (Spring 2024) -
Independent Study
PCOL 499 (Spring 2024) -
Pharmaceutics Research
PHSC 596C (Spring 2024) -
Research
PHSC 900 (Spring 2024) -
Directed Research
BME 492 (Fall 2023) -
Drug Delivery Systems
PCOL 355 (Fall 2023) -
Independent Study
PCOL 299 (Fall 2023) -
Introduction to Pharmacology
PCOL 501 (Fall 2023) -
Pharmaceutics Research
PHSC 596C (Fall 2023) -
Research
PHSC 900 (Fall 2023)
2022-23 Courses
-
Honors Independent Study
BME 299H (Spring 2023) -
Honors Thesis
PCOL 498H (Spring 2023) -
Pharmaceutics Research
PHSC 596C (Spring 2023) -
Research
PHSC 900 (Spring 2023) -
Drug Delivery Systems
PCOL 355 (Fall 2022) -
Honors Thesis
PCOL 498H (Fall 2022) -
Independent Study
PCOL 399 (Fall 2022) -
Introduction to Pharmacology
PCOL 501 (Fall 2022) -
Introduction to Pharmacology
PHSC 501 (Fall 2022)
2021-22 Courses
-
Honors Thesis
PSIO 498H (Spring 2022) -
Independent Study
PCOL 399 (Spring 2022) -
Directed Research
MCB 792 (Fall 2021) -
Drug Delivery Systems
PCOL 355 (Fall 2021) -
Honors Thesis
PSIO 498H (Fall 2021) -
Independent Study
NSCS 399 (Fall 2021) -
Introduction to Pharmacology
PCOL 501 (Fall 2021) -
Introduction to Pharmacology
PHSC 501 (Fall 2021) -
Pharmaceutics
PHSC 502 (Fall 2021) -
Pharmaceutics/Biopharmaceutics
PHPR 802 (Fall 2021)
2020-21 Courses
-
Independent Study
NSCS 399 (Spring 2021) -
Drug Delivery Systems
PCOL 355 (Fall 2020) -
Independent Study
PCOL 399 (Fall 2020) -
Introduction to Pharmacology
PCOL 501 (Fall 2020) -
Introduction to Pharmacology
PHSC 501 (Fall 2020) -
Pharmaceutics
PHSC 502 (Fall 2020) -
Pharmaceutics/Biopharmaceutics
PHPR 802 (Fall 2020)
2019-20 Courses
-
Independent Study
PCOL 899 (Spring 2020) -
Pharmaceutics Research
PHSC 596C (Spring 2020) -
Research
PHSC 900 (Spring 2020) -
Drug Delivery Systems
PCOL 355 (Fall 2019) -
Independent Study
PCOL 399 (Fall 2019) -
Independent Study
PCOL 499 (Fall 2019) -
Independent Study
PCOL 899 (Fall 2019) -
Introduction to Research
MCB 795A (Fall 2019) -
Pharmaceutics/Biopharmaceutics
PHPR 802 (Fall 2019)
Scholarly Contributions
Journals/Publications
- Li, W., Gonzalez, K. M., Chung, J., Kim, M., & Lu, J. (2022). Surface-modified nanotherapeutics targeting atherosclerosis. Biomaterials science, 10(19), 5459-5471.More infoAtherosclerosis is a chronic and metabolic-related disease that is a serious threat to human health. Currently available diagnostic and therapeutic measures for atherosclerosis lack adequate efficiency which requires promising alternative approaches. Nanotechnology-based nano-delivery systems allow for new perspectives for atherosclerosis therapy. Surface-modified nanoparticles could achieve highly effective therapeutic effects by binding to specific receptors that are abnormally overexpressed in atherosclerosis, with less adverse effects on non-target tissues. The main purpose of this review is to summarize the research progress and design ideas to target atherosclerosis using a variety of ligand-modified nanoparticle systems, discuss the shortcomings of current vector design, and look at future development directions. We hope that this review will provide novel research strategies for the design and development of nanotherapeutics targeting atherosclerosis.
- Wang, Z., Cordova, L. E., Chalasani, P., & Lu, J. (2022). Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy. Molecular pharmaceutics, 19(12), 4665-4674.More infoIn this study, we focus on investigating the therapeutic effects of camptothesome on treating metastatic triple-negative breast cancer (TNBC). We elucidate that camptothesome elicited stronger immunogenic cell death (ICD) compared to free camptothecin (CPT) and Onivyde in 4T1 TNBC cells. In addition, camptothesome is mainly internalized by the 4T1 and MDA-MB-231 cells through clathrin-mediated endocytosis based on the results of flow cytometry. Through real-time Lago optical imaging, camptothesome shows excellent tumor-targeting efficiency in orthotopic TNBC tumors. We demonstrate that camptothesome can upregulate programmed death-ligand 1 (PD-L1) in 4T1 tumors in an interferon gamma (IFN-γ)-dependent manner. Furthermore, the anti-TNBC efficacy studies reveal that camptothesome is superior to Onivyde and markedly potentiates PD-L1 immune checkpoint blockade therapy with complete lung metastasis remission in an orthotopic 4T1-Luc2 tumor model. This combination therapy eliciting robust cytotoxic T lymphocytes (CTL) response via boosting tumor-infiltrating cluster of differentiation 8 (CD8), calreticulin (CRT), high mobility group box 1 protein (HMGB-1), low-density lipoprotein receptor-related protein 1 (LRP1), IFN-γ, and granzyme B. Our work corroborates the promise of camptothesome in favorably modulating tumor immune microenvironment via inducing ICD to fortify the PD-L1 checkpoint blockade therapy for improved treatment of intractable TNBC.
- Wang, Z., Li, W., Park, J., Gonzalez, K. M., Scott, A. J., & Lu, J. (2022). Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade. Journal of controlled release : official journal of the Controlled Release Society, 349, 929-939.More infoCamptothesome is an innovative nanovesicle therapeutic comprising the sphingomyelin-derived camptothecin (CPT) lipid bilayer. In this work, we deciphered that Camptothesome was taken up by colorectal cancer (CRC) cells through primarily the clathrin-mediated endocytotic pathway and displayed the potential of eliciting robust immunogenic cancer cell death (ICD) via upregulating calreticulin, high mobility group box 1 protein (HMGB-1), and adenosine triphosphate (ATP), three hallmarks involved in the induction of ICD. In addition, use of dying MC38 tumor cells treated with Camptothesome as vaccine prevented tumor growth in 60% mice that received subsequent injection of live MC38 cells on the contralateral flank, validating Camptothesome was a legitimate ICD inducer in vivo. Camptothesome markedly reduced the acute bone marrow toxicity and gastrointestinal mucositis associated with free CPT and beat free CPT and Onivyde on anti-CRC efficacy and immune responses in a partially interferon gamma (IFN-γ)-dependent manner. Furthermore, Camptothesome enhanced the efficacy of immune checkpoint inhibitors to shrink late-stage orthotopic MC38 CRC tumors with diminished tumor metastasis and markedly prolonged mice survival.
Presentations
- Lu, J. (2022). Sphingomyelin-based nanomedicine for enhanced cancer therapy. 4th International Webinar on Pharmaceutics & Novel Drug Delivery SystemsImpact Conferences.